Cure Ventures

Cure Ventures is a life sciences venture capital firm established in 2021, dedicated to investing in de novo company formation around groundbreaking curative technologies. The firm focuses on early-stage investments in medical and biotechnology, particularly in new therapeutics. Their investment strategy is built on a seed funding model to de-risk scientific endeavors, leveraging genetic validation to increase the probability of success, and embedding Cure operators to collaborate with founders on day-to-day decision-making.

Founded in 2021, Cure Ventures was established by a network of highly accomplished industry veterans, including Managing Partners Richard Lim, David Fallace, and Lou Tartaglia. The founders aimed to eradicate life-debilitating and life-ending diseases with curative technologies, believing that people, not just capital, drive life-changing therapeutics. They committed to working closely with entrepreneurs, operationalizing capital, and acting as "sweat equity partners" to guide companies from inception to successful outcomes.

Cure Ventures has built a diverse portfolio of companies focused on addressing significant challenges in the life sciences sector. Notable investments include Aevum, which is developing therapeutics for Parkinson's disease; Alessatherapeutics, focused on anti-androgen therapy for prostate diseases; Cenos, creating a blood-brain barrier shuttle platform; Clasp, pioneering precision immuno-oncology; Crosslink, engineering cancer medicines; Kobuk, developing precision biologics for autoimmune diseases; Permeasis, utilizing proprietary delivery technology for intracellular biologics; Recuro, an integrated digital health solutions company; Tasca Therapeutics, developing small molecule drugs for oncology; Tortugas, developing therapeutics for neurological diseases; Triton Therapeutics, a clinical-stage company for autoimmune and fibrotic diseases; and XenImmune, leveraging immune responses to target tumors. [cite: 1 in previous turn, 2 in previous turn]

The Cure Ventures team comprises experienced professionals with decades of drug discovery expertise, many with FDA approvals to their names. Managing Partners Richard Lim, David Fallace, and Lou Tartaglia bring extensive backgrounds in biotech leadership and venture capital. The firm also includes partners like Jeff Jonas and Al Robichaud, further expanding their expertise in working with biotech entrepreneurs to develop therapeutics. Their culture is founded on respect for people and science, emphasizing data-driven pragmatism and independent thinking.